Drug profile · INN
mobocertinib
EXKIVITY
mobocertinib (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01EB
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — mobocertinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
mobocertinib (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda.
Key facts
INN mobocertinib
Brand EXKIVITY
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EB
Originator Takeda
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mobocertinib?
mobocertinib (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda.
What is the brand name for mobocertinib?
EXKIVITY is a marketed brand name for mobocertinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.